Please assess the completion status of the following clinical trial:

Trial Title: Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of acute viral hepatitis (\<1 month) as manifested by a combination of the following symptoms: jaundice, dark-colored urine, light-colored stools, pruritus, pruritic red hives, fever, nausea, vomiting, anorexia, aversion to smoking and right upper abdominal discomfort, pain or feeling of pressure.~* Serum ALT level \> 2.5 times the upper limit of normal.~* Albumin level \>3.5 gm/dl~* Negative anti-HCV antibody~* Males and females \>= 18 years of age.~* Subject has given written informed consent. If patient is between 18 and 21 years parents/legal guardian have/has also signed the informed consent form.~* The subject is able and willing to undertake all study-required procedures and has the ability to take oral medications.~Exclusion Criteria:~* Subjects \< 18 years of age~* Pregnant or breastfeeding women~* Suspected hypersensitivity to silymarin or multivitamins~* Advanced liver disease (e.g. ascites, bleeding esophageal varices and hepatic encephalopathy)~* Chronic liver disease as cirrhosis~* Subjects with positive anti-HCV antibody~* Simultaneous elevation of bilirubin \> 10 mg/dl along with an ALT level between 100 and 150 U/L~* Platelets count \<150,000~* Subjects with morbid obesity i.e. a Body Mass Index (BMI) \> 40~* Subjects with severe illness, e.g., multisystem failure, cancer or poorly controlled diabetes i.e. known diabetic with Hemoglobin A1C (HbA1C)\>7%~* Obvious history of drug-induced acute hepatitis. A careful history of all medications, pesticide and other hepatotoxic exposures occurring within one month prior to symptom onset will be taken. If a patient is unaware of the name of the drugs, (s)he will be asked to bring it for inspection.~* Current use of Silymarin or recent use within past two weeks.~* Other conditions, which in the opinion of the investigators, makes the patient unsuitable for enrollment or could interfere with his/her participation in, and completion of, the protocol (e.g. severe mental illness)~* The subject is currently participating in any clinical trial (marketed product or otherwise), or has done so within 30 days or 5 half-lives (whichever is longer) prior to screening visit~* History or current drug or alcohol abuse~* Female patient with childbearing potential without negative pregnancy test~* Patient is known to be HIV positive.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 280 mg of Silymarin administered three times daily for 4 weeks; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)
- 3 (Type: PLACEBO_COMPARATOR): Placebo: Lactose monohydrate; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)
- 2. (Type: EXPERIMENTAL): 420 mg silymarin three times daily for four weeks; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).